Neurological complications caused by SARS-CoV-2
- PMID: 39291997
- PMCID: PMC11629622
- DOI: 10.1128/cmr.00131-24
Neurological complications caused by SARS-CoV-2
Abstract
SUMMARYSARS-CoV-2 can not only cause respiratory symptoms but also lead to neurological complications. Research has shown that more than 30% of SARS-CoV-2 patients present neurologic symptoms during COVID-19 (A. Pezzini and A. Padovani, Nat Rev Neurol 16:636-644, 2020, https://doi.org/10.1038/s41582-020-0398-3). Increasing evidence suggests that SARS-CoV-2 can invade both the central nervous system (CNS) (M.S. Xydakis, M.W. Albers, E.H. Holbrook, et al. Lancet Neurol 20: 753-761, 2021 https://doi.org/10.1016/S1474-4422(21)00182-4 ) and the peripheral nervous system (PNS) (M.N. Soares, M. Eggelbusch, E. Naddaf, et al. J Cachexia Sarcopenia Muscle 13:11-22, 2022, https://doi.org/10.1002/jcsm.12896), resulting in a variety of neurological disorders. This review summarized the CNS complications caused by SARS-CoV-2 infection, including encephalopathy, neurodegenerative diseases, and delirium. Additionally, some PNS disorders such as skeletal muscle damage and inflammation, anosmia, smell or taste impairment, myasthenia gravis, Guillain-Barré syndrome, ICU-acquired weakness, and post-acute sequelae of COVID-19 were described. Furthermore, the mechanisms underlying SARS-CoV-2-induced neurological disorders were also discussed, including entering the brain through retrograde neuronal or hematogenous routes, disrupting the normal function of the CNS through cytokine storms, inducing cerebral ischemia or hypoxia, thus leading to neurological complications. Moreover, an overview of long-COVID-19 symptoms is provided, along with some recommendations for care and therapeutic approaches of COVID-19 patients experiencing neurological complications.
Keywords: COVID-19; SARS-CoV-2; central nervous system; long-COVID-19; neurological disorders; peripheral nervous system.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Antibody tests for identification of current and past infection with SARS-CoV-2.Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2. Cochrane Database Syst Rev. 2022. PMID: 36394900 Free PMC article.
-
Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.Curr Neurol Neurosci Rep. 2025 Jul 1;25(1):45. doi: 10.1007/s11910-025-01432-8. Curr Neurol Neurosci Rep. 2025. PMID: 40591029 Review.
-
Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.Cochrane Database Syst Rev. 2022 May 6;5(5):CD015112. doi: 10.1002/14651858.CD015112.pub2. Cochrane Database Syst Rev. 2022. Update in: Cochrane Database Syst Rev. 2024 Apr 10;4:CD015112. doi: 10.1002/14651858.CD015112.pub3. PMID: 35514111 Free PMC article. Updated.
-
The Role of TDP-43 in SARS-CoV-2-Related Neurodegenerative Changes.Viruses. 2025 May 19;17(5):724. doi: 10.3390/v17050724. Viruses. 2025. PMID: 40431734 Free PMC article. Review.
Cited by
-
Infections with Chlamydia pneumoniae and SARS-CoV-2 and Alzheimer's disease pathogenesis.Front Aging Neurosci. 2025 Jun 13;17:1587782. doi: 10.3389/fnagi.2025.1587782. eCollection 2025. Front Aging Neurosci. 2025. PMID: 40584180 Free PMC article. Review.
-
Elucidating SARS-CoV-2 neurotropism: a comprehensive Mendelian randomization study on cerebrospinal fluid biomarkers and their relevance to COVID-19 neurological manifestations.Virol J. 2025 Apr 28;22(1):123. doi: 10.1186/s12985-025-02754-2. Virol J. 2025. PMID: 40296111 Free PMC article.
-
Neurologic symptoms as a hallmark of glymphatic alteration in recovered patients with COVID-19.BMC Neurol. 2025 Apr 28;25(1):187. doi: 10.1186/s12883-025-04198-1. BMC Neurol. 2025. PMID: 40295959 Free PMC article.
-
The GPR4 antagonist NE-52-QQ57 increases survival, mitigates the hyperinflammatory response and reduces viral load in SARS-CoV-2-infected K18-hACE2 transgenic mice.Front Pharmacol. 2025 Jul 9;16:1549296. doi: 10.3389/fphar.2025.1549296. eCollection 2025. Front Pharmacol. 2025. PMID: 40703349 Free PMC article.
-
SARS-CoV-2 and neurotropism: evidence, gaps and reflections.J Med Microbiol. 2025 Jun;74(6):002016. doi: 10.1099/jmm.0.002016. J Med Microbiol. 2025. PMID: 40522851 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
- 82202492/MOST | National Natural Science Foundation of China (NSFC)
- 2020YFA0712102/MOST | National Key Research and Development Program of China (NKPs)
- QNTD2023-01/MOE | Fundamental Research Funds for the Central Universities (Fundamental Research Fund for the Central Universities)
- 2023BINCMCF28/Nutrition and Care of Maternal & Child Research Project of Biotime Institute of Nutrition & Care
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous